羅氟司特治療穩(wěn)定期COPD療效與安全性的系統(tǒng)評價
發(fā)布時間：2019-02-14 10:33
【摘要】：目的系統(tǒng)評價羅氟司特在治療慢性阻塞性肺疾病(COPD)的療效及安全性,以便于對臨床治療提供參考。方法計算機(jī)檢索PubMed、Web of Scinece、Springer link、Ovid、clinicaltrials.gov、CBM、Wangfang Date、CJFD等數(shù)據(jù)庫,制定納入及排除的試驗標(biāo)準(zhǔn),納入比較羅氟司特和安慰劑治療COPD的隨機(jī)對照試驗(RCT),檢索時間為建庫至2014年12月,提取相關(guān)數(shù)據(jù),并評估納入試驗的方法學(xué)質(zhì)量后,采用Rev Man 5.3軟件進(jìn)行統(tǒng)計分析。結(jié)果共納入了10個RCT。Meta分析結(jié)果顯示:(1)羅氟司特能顯著改善COPD患者的pre-FEV1[WMD=57.04ml,95%CI(45.22,68.85),P0.00001],同時改善其他肺功能指標(biāo);(2)羅氟司特可以明顯減少COPD急性加重率[RR=0.84,95%CI(0.75,0.94),P=0.002],改善COPD患者TDI評分[WMD=0.23,95%CI[0.04,0.42],P=0.02],但不能改善SGRQ評分[WMD=-0.48,95%CI(-2.39,1.43),P=0.63];(3)羅氟司特組較安慰劑組的不良事件發(fā)生率增加,表現(xiàn)為腹瀉、惡心、頭痛、體重減輕等。結(jié)論羅氟司特治療COPD患者可以顯著改善患者的肺功能、減少COPD急性加重率,具有較好的安全性。
[Abstract]:Objective to evaluate the efficacy and safety of roflostast in the treatment of chronic obstructive pulmonary disease (COPD). Methods PubMed,Web of Scinece,Springer link,Ovid,clinicaltrials.gov,CBM,Wangfang Date,CJFD and other databases were searched, and the criteria for inclusion and exclusion were established, and the randomized controlled trial (RCT), was used to compare roflustast with placebo in COPD. The retrieval time is from the construction of the database to December 2014. After extracting the relevant data and evaluating the quality of the methodology included in the experiment, the statistical analysis is carried out with Rev Man 5.3 software. Results the results of 10 RCT.Meta analysis showed that: (1) roflustrast could significantly improve pre-FEV1 [WMD=57.04ml,95%CI (45.2248.85), P0.00001] in patients with COPD, and improve other pulmonary function indexes at the same time; (2) roflustrast could significantly reduce the acute exacerbation rate of COPD [RR=0.84,95%CI (0.75-0.94), P0. 002], and improve the TDI score of COPD patients [WMD=0.23,95%CI [0.04 鹵0.42], P0. 02]. But the SGRQ score was not improved [WMD=-0.48,95%CI (-2.39 鹵1.43), P < 0.63]; (3) the incidence of adverse events in roflustast group was higher than that in placebo group, including diarrhea, nausea, headache, weight loss and so on. Conclusion roflostatin can significantly improve the pulmonary function and reduce the acute exacerbation rate of COPD in patients with COPD.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R563.9
本文編號：2422127
[Abstract]:Objective to evaluate the efficacy and safety of roflostast in the treatment of chronic obstructive pulmonary disease (COPD). Methods PubMed,Web of Scinece,Springer link,Ovid,clinicaltrials.gov,CBM,Wangfang Date,CJFD and other databases were searched, and the criteria for inclusion and exclusion were established, and the randomized controlled trial (RCT), was used to compare roflustast with placebo in COPD. The retrieval time is from the construction of the database to December 2014. After extracting the relevant data and evaluating the quality of the methodology included in the experiment, the statistical analysis is carried out with Rev Man 5.3 software. Results the results of 10 RCT.Meta analysis showed that: (1) roflustrast could significantly improve pre-FEV1 [WMD=57.04ml,95%CI (45.2248.85), P0.00001] in patients with COPD, and improve other pulmonary function indexes at the same time; (2) roflustrast could significantly reduce the acute exacerbation rate of COPD [RR=0.84,95%CI (0.75-0.94), P0. 002], and improve the TDI score of COPD patients [WMD=0.23,95%CI [0.04 鹵0.42], P0. 02]. But the SGRQ score was not improved [WMD=-0.48,95%CI (-2.39 鹵1.43), P < 0.63]; (3) the incidence of adverse events in roflustast group was higher than that in placebo group, including diarrhea, nausea, headache, weight loss and so on. Conclusion roflostatin can significantly improve the pulmonary function and reduce the acute exacerbation rate of COPD in patients with COPD.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R563.9
【參考文獻(xiàn)】
相關(guān)期刊論文 前1條
1 馮桂山;宋寧;段爭;吳雅莉;;羅氟司特治療慢性阻塞性肺疾病藥理作用的臨床前研究現(xiàn)況[J];臨床薈萃;2011年04期
，本文編號：2422127
本文鏈接：http://sikaile.net/yixuelunwen/huxijib/2422127.html
最近更新
教材專著
